جميع الدراسات
التوظيفالمرحلة 3تدخلي

تجربة سريرية لـ Sac-TMT في الأشخاص المصابين بسرطان المبيض المتقدم غير الإيجابي لـ HRD (MK-2870-021)

Researchers are exploring new treatments for advanced ovarian cancer. After initial surgery and chemotherapy, many women receive maintenance treatment to prevent the cancer from returning or growing. This study is testing if a new targeted therapy, called sacituzumab tirumotecan (sac-TMT), either alone or with another standard drug called bevacizumab, can extend the time before the cancer worsens. This is compared to current standard care options, which include bevacizumab maintenance or close observation. The aim is to find out if sac-TMT can help women live longer without their cancer progressing, for those whose cancer has responded well to their first round of treatment.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
Merck Sharp & Dohme LLC
الهدف من التسجيل
900
ابدأ
16 فبراير 2026
التاريخ المتوقع للانتهاء
25 Feb 2033

ما هو موضوع هذه الدراسة؟

When someone is diagnosed with ovarian cancer, doctors often try to remove as much of the cancer as possible with surgery. After surgery, chemotherapy is typically given to kill any remaining cancer cells. The next step is often to keep the cancer from coming back or growing, and this is where this study comes in.

Currently, after chemotherapy, some people receive maintenance treatment, which is like a protective shield designed to keep the cancer at bay. Bevacizumab is a common maintenance drug. Other times, doctors might just keep a close eye on the cancer with regular check-ups. This study is trying to understand if a new medicine, called sacituzumab tirumotecan (sac-TMT), can be a better maintenance treatment.

Sac-TMT is a type of targeted therapy, which means it's designed to specifically attack cancer cells while trying to leave healthy cells alone. The main goal of this research is to see if giving sac-TMT, either by itself or along with bevacizumab, helps women with ovarian cancer live longer without their cancer getting worse, compared to the usual treatments. This is especially for women whose cancer has responded well to their first set of treatments.

النقاط الرئيسية

  • This study is testing a new drug for advanced ovarian cancer after initial treatment.
  • It aims to see if sac-TMT (a targeted therapy) can keep cancer from worsening longer.
  • Participation involves receiving either the new drug or standard care, assigned by chance.
  • This is a Phase 3 trial, meaning it's a large study comparing the new treatment to existing ones.
  • It's for women whose cancer responded well to their first round of chemotherapy.
  • لديك الحق في مغادرة الدراسة في أي وقت.

من قد يكون مؤهلاً؟

This study is looking for women who have advanced ovarian cancer, or similar cancers of the fallopian tube or peritoneum, that has been confirmed by a doctor. You would need to have already had surgery and completed your first course of chemotherapy, and your cancer should have responded well to that treatment – meaning it’s stable, partly gone, completely gone, or not detectable.

There are also some important health checks. For example, if you have HIV, it needs to be well-controlled. Similar rules apply if you have hepatitis B or C – these conditions need to be managed and not active. You would also need to provide a sample of your tumor tissue that hasn't been treated with radiation before.

However, there are reasons why you might not be able to join. For instance, if your cancer is a very specific type (like certain low-grade or borderline tumors), or if you have cancer that has spread to your brain or spinal cord. Other health conditions like severe eye disease, active inflammatory bowel disease needing strong medication, or serious, uncontrolled heart or blood vessel problems would also prevent you from taking part. You also can’t have had systemic cancer treatment (other than your initial chemotherapy) or certain vaccinations recently, or another type of active cancer or serious infection.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Have I been diagnosed with advanced ovarian, fallopian tube, or peritoneal cancer?
  2. Have I completed surgery and my first course of platinum-based chemotherapy?
  3. Has my cancer responded well to my first chemotherapy (stable, getting better, or undetectable)?
  4. Do I have any other serious uncontrolled health conditions like heart problems or active inflammatory bowel disease?
  5. Do I have any cancer spread to my brain or spinal cord?
  6. Am I over 18 years old and female?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you would first go through a screening process to make sure the study is right for you. This might involve additional hospital visits, more tests, and discussions with the study team. Once enrolled, you would receive either the study medicine (sac-TMT, with or without bevacizumab) or standard care, which could be bevacizumab or observation, depending on which group you are assigned to. This is done by chance, like flipping a coin. You'll need regular appointments, usually at the clinic, for check-ups, blood tests, and to receive your treatment. Doctors will closely monitor your health and how your cancer is responding. The duration of your participation will vary depending on your treatment plan and how your body responds. The study team will explain the full schedule of visits and assessments to you in detail.

المخاطر والفوائد المحتملة

Participating in research studies like this means we are hoping to find better ways to treat ovarian cancer. A potential benefit of joining could be receiving a new treatment, sac-TMT, which might keep your cancer from getting worse for longer than current treatments. However, like all medicines, sac-TMT can have side effects, which the study team will discuss with you. There’s also no guarantee that the new treatment will be better or even as good as the standard options. You could also be assigned to the standard care group. It's very important to remember that participating in any clinical trial is entirely voluntary, and you are free to withdraw at any time for any reason without it affecting your usual medical care.

Locations (177)

  • University of Alabama - Birmingham ( Site 0058)
    الرمز البريدي المؤكد
    برمنغهام، الولايات المتحدة· التوظيف
  • UCSD Moores Cancer Center ( Site 0038)
    الرمز البريدي المؤكد
    لا جولا، الولايات المتحدة· التوظيف
  • John Muir Health Cancer Center ( Site 0069)
    الرمز البريدي المؤكد
    والنوت كريك، الولايات المتحدة· التوظيف
  • Anschutz Cancer Pavilion ( Site 0049)
    الرمز البريدي المؤكد
    أورورا، الولايات المتحدة· التوظيف
  • University of Colorado Health - Highlands Ranch Hospital ( Site 0094)
    الرمز البريدي المؤكد
    هايلاندز رانش، الولايات المتحدة· التوظيف
  • Mount Sinai Cancer Center ( Site 0029)
    الرمز البريدي المؤكد
    ميامي بيتش، الولايات المتحدة· التوظيف
  • Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085)
    الرمز البريدي المؤكد
    أورلاندو، الولايات المتحدة· التوظيف
  • Winship Cancer Institute of Emory University ( Site 0037)
    الرمز البريدي المؤكد
    أتلانتا، الولايات المتحدة· التوظيف
  • Illinois Cancer Specialists (ICS) ( Site 8009)
    الرمز البريدي المؤكد
    أرلينغتون هايتس، الولايات المتحدة· التوظيف
  • Parkview Research Center at Parkview Regional Medical Center ( Site 0055)
    الرمز البريدي المؤكد
    فورت واين، الولايات المتحدة· التوظيف
  • Franciscan Health Indianapolis ( Site 0081)
    الرمز البريدي المؤكد
    إنديانابوليس، الولايات المتحدة· التوظيف
  • Women's Cancer Care ( Site 0018)
    الرمز البريدي المؤكد
    Covington, United States· التوظيف

أسئلة شائعة

What is 'advanced ovarian cancer'?

Advanced ovarian cancer means the cancer has spread beyond the ovaries and may have reached other parts of the body.

What is a 'targeted therapy'?

A targeted therapy is a type of medicine that specifically attacks certain parts of cancer cells, aiming to cause less harm to healthy cells.

ما هو 'العلاج الوقائي'؟

After initial treatment like surgery and chemotherapy, maintenance treatment is given to help keep the cancer from growing, spreading, or coming back.

Will I definitely receive the new medicine?

No, participants are randomly assigned to either receive the new study medicine (with or without bevacizumab) or standard care, such as bevacizumab or observation.

كم من الوقت سأكون في الدراسة؟

The length of time you'd be involved in the study can vary depending on your treatment plan and how your cancer responds. The doctors will explain this to you.

كيفية معرفة المزيد

رقم مجاني

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Clinical Trial of Sac-TMT in People With Non-HRD Positive … "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.